Morgan Stanley Reiterates Overweight Rating on Sana Biotechnology (SANA) after "meaningful platform level de-risking event"
Tweet Send to a Friend
Morgan Stanley analyst Maxwell Skor reiterated an Overweight rating and $12.00 price target on Sana Biotechnology (NASDAQ: SANA)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
